NASDAQ
PDLI

PDL BioPharma, Inc

Prices are adjusted according to historical splits.

PDL BioPharma, Inc Stock Price

Vitals

Today's Low:
$2.4700
Today's High:
$2.4700
Open Price:
$2.4700
52W Low:
$2.25
52W High:
$3.86
Prev. Close:
$2.4700
Volume:
0

Company Statistics

Market Cap.:
$0.297 billion
Book Value:
3.69
Revenue TTM:
$0.028 billion
Operating Margin TTM:
-166.77%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-4.1%
Return on Equity TTM:
-7.36%

Company Profile

PDL BioPharma, Inc had its IPO on 1992-01-29 under the ticker symbol PDLI.

The company operates in the sector and industry. PDL BioPharma, Inc has a staff strength of 109 employees.

Stock update

Shares of PDL BioPharma, Inc opened at $2.47 at the start of the last trading session i.e. 2022-01-18.

The stocks traded within a range of $2.47 - $2.47, and closed at $2.47.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of PDL BioPharma, Inc have increased by +23.5%.

PDL BioPharma, Inc's Key Ratios

PDL BioPharma, Inc has a market cap of $0.297 billion, indicating a price to book ratio of 0.8593 and a price to sales ratio of 7.1337.

In the last 12-months PDL BioPharma, Inc’s revenue was $0.028 billion with a gross profit of $0.000 billion and an EBITDA of $-0.004 billion. The EBITDA ratio measures PDL BioPharma, Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, PDL BioPharma, Inc’s operating margin was -166.77% while its return on assets stood at -4.1% with a return of equity of -7.36%.

In Q2, PDL BioPharma, Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 30.1%.

PDL BioPharma, Inc’s PE and PEG Ratio

Forward PE
64.9351
Trailing PE
0
PEG
0.4

Its diluted EPS in the last 12-months stands at $-1.324 per share while it has a forward price to earnings multiple of 64.9351 and a PEG multiple of 0.4. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into PDL BioPharma, Inc’s profitability.

PDL BioPharma, Inc stock is trading at a EV to sales ratio of 5.1996 and a EV to EBITDA ratio of 6.9735. Its price to sales ratio in the trailing 12-months stood at 7.1337.

PDL BioPharma, Inc stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

PDL BioPharma, Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

PDL BioPharma, Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

PDL BioPharma, Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, PDL BioPharma, Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, PDL BioPharma, Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$2.47
52-Week High
$3.86
52-Week Low
$2.25
Analyst Target Price
$3

PDL BioPharma, Inc stock is currently trading at $2.47 per share. It touched a 52-week high of $3.86 and a 52-week low of $3.86. Analysts tracking the stock have a 12-month average target price of $3.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 11.75 indicating a short percent outstanding of 11%.

Around 355.4% of the company’s stock are held by insiders while 8391.5% are held by institutions.

Frequently Asked Questions About PDL BioPharma, Inc

The stock symbol (also called stock or share ticker) of PDL BioPharma, Inc is PDLI

The IPO of PDL BioPharma, Inc took place on 1992-01-29

Similar Industry Stocks ()

Last Price
Chg
Chg%
$59.43
2.26
+3.95%
$4.58
-0.07
-1.51%
$2.25
-0.18
-7.41%
$21.11
-0.71
-3.25%
$22.89
-0.79
-3.34%
$1.91
-0.06
-3.05%
$70.93
0.55
+0.78%
Fabrinet (FN)
$113.2
-3.07
-2.64%
$30.81
-0.82
-2.59%
$17.17
-1.09
-5.97%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in North America, Europe, Asia, and internationally. The company operates through Medical Devices, Strategic Positions, Pharmaceutical, and Income Generating Assets segments. The Medical Devices segment offers LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The Strategic Positions segment develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Perjeta, Kadcyla, and Tysabri. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Address

932 Southwood Boulevard, Incline Village, NV, United States, 89451